Brivaracetam patent?

See the DrugPatentWatch profile for Brivaracetam

Brivaracetam Patent Exclusivity and Biosimilars

Brivaracetam is a medication used to treat partial-onset seizures, a type of epilepsy [1]. It is sold under the brand name Briviact, developed by UCB Pharma [2]. The patent landscape for brivaracetam is complex, and understanding its exclusivity and potential biosimilarity is crucial for the pharmaceutical industry and patients.

Why are Companies Challenging this Patent?

Several companies, including Teva Pharmaceuticals and Sunovion Pharmaceuticals, have challenged the exclusivity of brivaracetam patents, which has resulted in delays and court battles [3]. The patent challenges raise questions about the potential for biosimilar drugs to enter the market before the original patent expires.

When Does Exclusivity Expire?

The patent for brivaracetam is set to expire in 2028, although specific dates may vary depending on the country and regional laws [4]. However, the exclusivity period for Briviact has been extended multiple times, and the exact expiration date for certain countries remains unclear.

Can Biosimilars Enter Before Patent Expiry?

Biosimilars are biologic drugs that are highly similar to existing medications, including branded biologics like brivaracetam. In the United States, biosimilars can enter the market four years before the original patent expires, provided they demonstrate significant bioequivalence [5]. However, the complexity of patent challenges and exclusivity extensions has created uncertainty about the timeline for biosimilars.

What Happens if Patent Challenges are Successful?

If the patent challenges succeed, biosimilars could enter the market sooner than expected, potentially leading to increased competition and lower prices for brivaracetam. Conversely, if the patent challenges fail, the exclusivity period may be extended, maintaining the market dominance of Briviact.

Clinical Data and Competition

Brivaracetam has shown effectiveness in treating partial-onset seizures in clinical trials, with a rapid onset of action and a relatively favorable safety profile [6]. As competitors challenge the patent, the clinical data supporting brivaracetam's efficacy and safety will remain crucial in maintaining its market position.

Sources:

[1] https://www.drugpatentwatch.com/Briviact/
[2] https://en.wikipedia.org/wiki/Brivaracetam
[3] https://www.reuters.com/article/uk-biosimilars-taked-ucb-pharma/teva-sunovion-pharmaceuticals-challenge-ucb-brivaracetam-patent-idUKL5N2P21LJ
[4] https://www.drugpatentwatch.com/Briviact/
[5] https://www.fda.gov/drugs/biosimilars/biosimilar-approval-process
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754753/

This article is based on publicly available information and should not be considered as investment advice. Always consult a medical professional and conduct thorough research before making any decisions about medications or investments.